The ARHGEF2 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from HeLa cells, engineered to disrupt the ARHGEF2 gene. This loss-of-function model abolishes expression of the Rho guanine nucleotide exchange factor GEF-H1, enabling investigation of ARHGEF2-dependent signaling. The polyclonal format provides a mixture of edited alleles, reducing clonal selection bias. Supplied as a growing culture, the product is intended for endpoint biomedical research applications.
The host cell line, HeLa, is an immortalized epithelial cell line originally isolated from a cervical adenocarcinoma of Henrietta Lacks in 1951. These cells are widely employed as a model system for human cancer biology, signal transduction, and host-pathogen interactions. HeLa cells exhibit a stable karyotype and rapid proliferation, making them suitable for genetic manipulation and high-throughput screening. Their cervical origin renders them particularly relevant for studying Rho GTPase signaling in the context of cervical carcinoma progression and metastasis.
ARHGEF2 encodes GEF-H1, a microtubule-associated Rho guanine nucleotide exchange factor. It activates RhoA by catalyzing GDP/GTP exchange, a process tightly regulated by microtubule sequestration. Upon microtubule depolymerization, GEF-H1 is released and stimulates RhoA, which in turn activates ROCK1/2 and mDia1. These effectors phosphorylate myosin light chain (MLC) and promote actin polymerization, driving stress fiber formation and focal adhesion maturation. Upstream kinases PAK1, PKA, and Aurora A phosphorylate GEF-H1 to modulate its localization and activity. At tight junctions, GEF-H1 interacts with 14-3-3 proteins, cingulin, and paracingulin, linking microtubule dynamics to cell adhesion. RhoA activation also triggers SRF/MAL-dependent transcription of cytoskeletal and proliferative genes, integrating signals from integrins, GPCRs (G12/13), and microtubule stability to coordinate cytoskeletal remodeling, cytokinesis, and gene expression.
In HeLa cells, ARHGEF2-mediated RhoA activation controls epithelial morphology, collective cell migration, and cytokinesis. Knockout of ARHGEF2 in this cervical carcinoma background provides a powerful tool to dissect GEF-H1 contributions to tumor invasion, metastatic dissemination, and tight junction permeability. The model also holds relevance for breast cancer, hepatocellular carcinoma, and inflammatory diseases, where ARHGEF2 is dysregulated. By eliminating endogenous GEF-H1, these polyclonal cells enable precise evaluation of Rho pathway-targeted therapeutics and functional crosstalk between microtubules and the actin cytoskeleton.
These polyclonal ARHGEF2 knockout cells are optimized for end-point functional analyses and are compatible with a range of assays. Typical applications include RhoA GTPase activation assays (G-LISA), Western blotting for phospho-MLC and total MLC, and immunofluorescence staining of F-actin to visualize stress fibers. The cells perform well in Transwell migration and invasion assays, cytokinesis index measurements, and RNA-seq-based transcriptomic profiling. They also facilitate screening of ROCK inhibitors and microtubule-targeting agents in a loss-of-function context. For further information, please contact Ascent Research.
